BioMarin Sets 2026 Revenue Range At $3.8 Billion To $3.9 Billion As One Customer Defers $70 Million

The CFO blamed order timing, not patient demand, and said Middle East conflict is straining customer cash flow.

Share
BioMarin Sets 2026 Revenue Range At $3.8 Billion To $3.9 Billion As One Customer Defers $70 Million

BioMarin, which develops medicines for rare genetic diseases, set a full-year revenue range of $3.8 billion to $3.9 billion after one international customer said it plans to defer orders totaling about $70 million, Chief Financial Officer Brian Mueller said on the company's earnings call Monday. He said the driver is "order timing and not underlying patient demand."

Deferred orders and a squeezed customer base

Mueller said the customer flagged during the third quarter that it intends to push back several expected orders. Some are already under contract for shipment, and the company expects to fill most of them between late fourth quarter and the first quarter of 2027, though "we cannot predict the exact timing."

A second factor is the prolonged Middle East conflict. Mueller said "customer liquidity and customer cash flow disruption have increased over the last two months." The company can usually offset swings in a full year, he said, but with two months left there are fewer offsets available.

Pressed by a Raymond James analyst on the arithmetic, Mueller said a little more than half of the $70 million is Voxogo, BioMarin's daily injection for achondroplasia, a form of short stature. A one-quarter deferral, he said, could push follow-on orders into 2027. Separately, a single Voxogo order expected in the third quarter is now planned for the fourth and is not part of the $70 million.

Why large buyers order unevenly

About two-thirds of BioMarin's business is outside the United States, Mueller said, largely with single-payer national health systems that tend to order big quantities irregularly. That is one reason the company does not guide by quarter, he said, though this deferral was large and uncertain enough to be reflected in the outlook.

Third-quarter revenue topped $1 billion for the first time, up 32% from a year earlier, helped by the Amicus acquisition. Voxogo revenue rose 12% to $245 million, and the number of children treated climbed about 17% worldwide.

Earnings guidance carries deal costs

Non-GAAP (adjusted) earnings per share guidance is now $2.80 to $3.10. Mueller said the Alesta acquisition lowers it by about $1.55 and the BMN 450 license for a Fabry disease therapy by about $0.32, and that neither deal was in the August guidance. Excluding the deals and the revenue change, he said, the midpoint is effectively unchanged from August.

Third-quarter adjusted earnings were 23 cents a share, reflecting charges tied to Alesta.

Voxogo outlook into 2027

Mueller said Voxogo is expected to keep growing in 2027, with a launch in hypochondroplasia offsetting possible share loss to competitors. BioMarin will guide for 2027 later.

CEO Alexander Hardy said the FDA's target date for Voxogo in hypochondroplasia is May 30, 2027. R&D chief Greg Friberg said the full-approval decision for achondroplasia has a February 28 target date.

Mueller said the underlying business "is performing strongly," and the company will update on 2027 when it issues guidance for that year.

Sources

More on BioMarin Pharmaceutical

All BioMarin Pharmaceutical (BMRN) coverage →